Physician profile
Mark Richards
NPI 1285895938
$10,015.00
in general payments reported to CMS, 2019-2025
41 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $257 · 2021: $4,581 · 2022: $1,551 · 2023: $558 · 2024: $854 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,659.53 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $1,198.29 | 2019-2025 | |
| Novo Nordisk INC | $1,115.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $529.29 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $519.08 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $462.56 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $422.66 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $269.29 | 2019-2022 | |
| Lilly USA, LLC | $222.87 | 2019-2023 | Jardiance, Mounjaro |
| Phathom Pharmaceuticals, INC. | $159.88 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $146.90 | 2019-2025 | Lagevrio |
| Dexcom, INC. | $118.31 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.51 | 2020-2022 | |
| Amgen INC. | $110.35 | 2021-2022 | |
| Amarin Pharma, INC. | $101.20 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.